BioVie Announces Completion Of Last Patient Evaluation Visit In The SUNRISE-PD Phase 2 Trial Evaluating Its Drug Candidate Bezisterim In Early Stage Parkinson's Disease

Benzinga Newsdesk www.benzinga.com Neutral 77.0%

Neg 0% Neu 77% Pos 0%

Comments

No comments yet. Be the first!